Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer

NCT00241449 ·Status: COMPLETED ·Phase: PHASE3

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

NCT00259090 ·Status: COMPLETED ·Phase: PHASE2

Parameters of Acceptability, Compliance and Efficacy of Fulvestrant in Post-menopausal Patients With Advance Breast Cancer

NCT00878930 ·Status: COMPLETED

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

NCT00570323 ·Status: COMPLETED ·Phase: PHASE2

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

NCT00944918 ·Status: COMPLETED ·Phase: PHASE3

Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole

NCT00543127 ·Status: TERMINATED ·Phase: PHASE3

Efficacy and Safety of 500mg of Fulvestrant

NCT00585507 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

NCT00754325 ·Status: COMPLETED ·Phase: PHASE2

Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors

NCT00253422 ·Status: COMPLETED ·Phase: PHASE3

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02374099 ·Status: TERMINATED ·Phase: PHASE2

Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

NCT00238316 ·Status: COMPLETED ·Phase: PHASE2

Study of Breast Cancer Prevention by Letrozole in High Risk Women

NCT00579826 ·Status: COMPLETED ·Phase: PHASE2

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

NCT05439499 ·Status: UNKNOWN ·Phase: PHASE3

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325 ·Status: COMPLETED ·Phase: PHASE3

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

NCT01171417 ·Status: COMPLETED

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

NCT06917313 ·Status: RECRUITING ·Phase: PHASE2

Letrozole in Preventing Breast Cancer in Healthy Postmenopausal Women at High Risk for Breast Cancer

NCT01077453 ·Status: COMPLETED ·Phase: PHASE1

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

NCT00146601 ·Status: COMPLETED ·Phase: PHASE2

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

NCT01553903 ·Status: COMPLETED ·Phase: PHASE4

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

NCT01602380 ·Status: COMPLETED ·Phase: PHASE3

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

NCT00237211 ·Status: COMPLETED ·Phase: PHASE2

Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women

NCT00237133 ·Status: COMPLETED ·Phase: PHASE4

Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects

NCT01183832 ·Status: COMPLETED

Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment

NCT01425294 ·Status: TERMINATED